| Literature DB >> 33276457 |
Yu-Chung Tsao1,2, Wen-Cheng Li2,3,4, Wei-Chung Yeh3, Steve Wen-Neng Ueng2,5, Sherry Yueh-Hsia Chiu6,7, Jau-Yuan Chen2,3.
Abstract
The aim of this study was to conduct a community-based study with a view to construct a detailed analysis about metabolic syndrome and the related risk factors of the indigenous population. This was an observational, population-based and cross-sectional study that was conducted in remote villages of an indigenous community in northern Taiwan between 2010 and 2013. A total of 586 participants, 275 men and 311 women, were eligible for analysis. The participants underwent a questionnaire survey that included demographic and health behavior issues. An anthropometric assessment and measurements of blood pressure were carried out including serum biochemical variables. Metabolic syndrome (MetS) was defined by following the criteria provided by the modified Adult Treatment Panel III (ATP III) criteria of the National Cholesterol Education Program (NCEP). Univariate and multiple logistic regressions were used to identify the risk factors for metabolic syndrome. The standardized prevalence rates of substance use (cigarette smoking, alcohol drinking and betel nut chewing) were significantly higher than the general population regardless of whether it was northern, central or southern Taiwan and this was especially the case with betel nut chewing in women. The prevalence rate of metabolic syndrome was 42.9% in the indigenous population with 41.3% in men and 44.4% in women, which was higher than for urban Taiwanese. In the multiple logistic regression models, we found that the significant associated factors for metabolic syndrome were older age, lower education level, high levels of uric acid, alanine transaminase (ALT), gamma-glutamyl transferase (γ-GT) and creatinine. A higher prevalence rate of metabolic syndrome and substance use were observed in the indigenous population compared with urban Taiwanese, especially in women.Entities:
Keywords: metabolic syndrome; rural health; substance usage indigenous people
Year: 2020 PMID: 33276457 PMCID: PMC7730304 DOI: 10.3390/ijerph17238958
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Geographical information of the remote area of the Fuxing District.
Background analysis of basic information, biomarkers and the prevalence of metabolic syndrome of the male and female population (n = 586).
| Variables | Total | Male | Female | |||||
|---|---|---|---|---|---|---|---|---|
| ( | ( | ( | (α = 0.05) | |||||
| Age | 49.3 | ±15.8 | 50.4 | ±16.9 | 48.4 | ±14.8 | 0.1217 | |
| Age | ||||||||
| <30 | 65 | (11.1) | 33 | (12.0) | 32 | (10.3) | 0.1361 | |
| 30–39 | 115 | (19.6) | 45 | (16.4) | 70 | (22.5) | ||
| 40–49 | 118 | (20.1) | 53 | (19.3) | 65 | (20.9) | ||
| 50–59 | 116 | (19.8) | 53 | (19.3) | 63 | (20.3) | ||
| 60–69 | 104 | (17.8) | 50 | (18.2) | 54 | (17.4) | ||
| >70 | 68 | (11.6) | 41 | (14.9) | 27 | (8.7) | ||
| Income (NTD, New Taiwan Dollars) | 0.0028 * | |||||||
| <10,000 | 295 | (61.3) | 114 | (53.8) | 181 | (67.3) | ||
| 10,000–29,999 | 140 | (29.1) | 69 | (32.6) | 71 | (26.4) | ||
| >30,000 | 46 | (9.6) | 29 | (13.7) | 17 | (6.3) | ||
| Unknown | 105 | 63 | 42 | |||||
| Education | 0.0382 * | |||||||
| ≤6 grade | 222 | (45.9) | 94 | (43.9) | 128 | (47.4) | ||
| 7–9 grade | 135 | (27.9) | 51 | (23.8) | 84 | (31.1) | ||
| 10–12 grade | 98 | (20.3) | 55 | (25.7) | 43 | (15.9) | ||
| College or higher | 29 | (6.0) | 14 | (6.5) | 15 | (5.6) | ||
| Unknown | 102 | 61 | 41 | |||||
| Current cigarette smoker | <0.0001 | |||||||
| No | 351 | (73.6) | 134 | (63.2) | 217 | (81.9) | ||
| Yes | 126 | (26.4) | 78 | (36.8) | 48 | (18.1) | ||
| Unknown | 109 | 63 | 46 | |||||
| Alcohol drinking habit | 0.0513 | |||||||
| No | 320 | (66.7) | 132 | (62.0) | 188 | (70.4) | ||
| Yes | 160 | (33.3) | 81 | (38.0) | 79 | (29.6) | ||
| Unknown | 106 | 62 | 44 | |||||
| Betel nut chewing habit | <0.0001 | |||||||
| No | 410 | (86.0) | 166 | (78.7) | 244 | (91.7) | ||
| Yes | 67 | (14.1) | 45 | (21.3) | 22 | (8.3) | ||
| Unknown | 109 | 64 | 45 | |||||
| DM | 0.1210 | |||||||
| No | 488 | (83.3) | 236 | (85.8) | 252 | (81.0) | ||
| Yes (FG ≥ 126 or with history) | 98 | (16.7) | 39 | (14.2) | 59 | (19.0) | ||
| Hypertension | 0.9494 | |||||||
| No | 281 | (50.6) | 131 | (50.8) | 150 | (50.5) | ||
| Yes (SBP ≥ 140 or DBP ≥ 90 or with history) | 274 | (49.4) | 127 | (49.2) | 147 | (49.5) | ||
| Unknown | 31 | 17 | 14 | |||||
| Metabolic syndrome | 0.4728 | |||||||
| No | 299 | (57.1) | 141 | (58.8) | 158 | (55.6) | ||
| Yes (ATP III Asian criteria) | 225 | (42.9) | 99 | (41.3) | 126 | (44.4) | ||
| Unknown | 62 | 35 | 27 | |||||
| Uric acid | <0.0001 | |||||||
| Normal | 475 | (81.1) | 198 | (72.0) | 277 | (89.1) | ||
| Abnormal (>8 mg/dL) | 111 | (18.9) | 77 | (28.0) | 34 | (10.9) | ||
| Total cholesterol | 0.0672 | |||||||
| Normal | 326 | (55.6) | 142 | (51.6) | 184 | (59.2) | ||
| Abnormal (≥200 mg/dL) | 260 | (44.4) | 133 | (48.4) | 127 | (40.8) | ||
| High-density lipoprotein cholesterol (HDL-C) | 0.0075 * | |||||||
| Normal | 385 | (65.7) | 196 | (71.3) | 189 | (60.8) | ||
| Abnormal (male < 40 or female < 50 mg/dL) | 201 | (34.3) | 79 | (28.7) | 122 | (39.2) | ||
| Triglyceride | 0.0453 * | |||||||
| Normal | 345 | (58.9) | 150 | (54.6) | 195 | (62.7) | ||
| Abnormal (≥150 mg/dL) | 241 | (41.1) | 125 | (45.5) | 116 | (37.3) | ||
| Aspartate transaminase (AST) | 0.2833 | |||||||
| Normal | 463 | (79.0) | 212 | (77.1) | 251 | (80.7) | ||
| Abnormal (>34 U/L) | 123 | (21.0) | 63 | (22.9) | 60 | (19.3) | ||
| Alanine transaminase (ALT) | 0.1390 | |||||||
| Normal | 463 | (79.0) | 210 | (76.4) | 253 | (81.4) | ||
| Abnormal (>36 U/L) | 123 | (21.0) | 65 | (23.6) | 58 | (18.7) | ||
| Gamma-Glutamyl Transferase (γ-GT) | 0.0019 * | |||||||
| Normal | 443 | (75.6) | 224 | (81.5) | 219 | (70.4) | ||
| Abnormal | 143 | (24.4) | 51 | (18.6) | 92 | (29.6) | ||
| Creatinine | 0.2333 | |||||||
| Normal | 566 | (96.6) | 263 | (95.6) | 303 | (97.4) | ||
| Abnormal | 20 | (3.4) | 12 | (4.4) | 8 | (2.6) | ||
| Hepatitis B surface antigen (HBsAg) | 0.6558 | |||||||
| Negative | 452 | (82.0) | 208 | (81.3) | 244 | (82.7) | ||
| Positive | 99 | (18.0) | 48 | (18.8) | 51 | (17.3) | ||
| Unknown | 35 | 19 | 16 | |||||
| Anti-HCV antibody | 0.2646 | |||||||
| Negative | 520 | (94.6) | 245 | (95.7) | 275 | (93.5) | ||
| Positive | 30 | (5.5) | 11 | (4.3) | 19 | (6.5) | ||
| Unknown | 36 | 19 | 17 | |||||
* p-Value < 0.05.
Crude and standardized prevalence of substance usage compared with other parts of Taiwan.
| Substance Use | Subjects | Fuxing District | Northern Taiwan 1 | Central Taiwan 1 | Southern Taiwan 1 | |
|---|---|---|---|---|---|---|
| Prevalence | Standardized Prevalence 1 | |||||
| Cigarette smoking | Total | 26.4 | 33.3 | 28.6 | 14.0 | 16.0 |
| Male | 36.8 | 45.3 | 59.1 | 53.7 | 52.3 | |
| Female | 18.1 | 25.9 | 9.4 | 2.5 | 2.7 | |
| Alcohol drinking | Total | 33.3 | 36.7 | 24.1 | 6.8 | 8.4 |
| Male | 38.0 | 39.1 | 47.6 | 23.7 | 27.9 | |
| Female | 29.6 | 35.0 | 9.4 | 1.7 | 1.7 | |
| Betel nut chewing | Total | 14.1 | 18.0 | 7.2 | 6.5 | 5.4 |
| Male | 21.3 | 31.9 | 18.1 | 28.9 | 23.3 | |
| Female | 8.3 | 10.0 | 0.8 | 0.3 | 0.4 | |
1 Standardized using the WHO 2000 world population, http://www.who.int/healthinfo/paper31.pdf. Total subjects: 586; male: 275, female: 311.
Results of univariate and multivariate regression models on possible variants comparing those with and without metabolic syndrome.
| Variables | Model 1 Univariate Regression | Model 2 Univariate Regression, Adjusted for Age and Gender | Model 3 Multivariate Regression, Adjusted for Age and Gender | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR | (95% CI) | aOR | (95% CI) | aOR ( | (95% CI) | ||||
| Gender | |||||||||
| Female | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| Male | 0.88 | (0.62, 1.25) | 0.4728 | 0.81 | (0.57, 1.17) | 0.2587 | 0.76 | (0.50, 1.16) | 0.2029 |
| Age | 1.03 | (1.02, 1.04) | <0.0001 | 1.03 | (1.02, 1.04) | <.0001 | 1.03 | (1.01, 1.04) | 0.0006 * |
| Age (years old) | |||||||||
| <30 | 1.00 | Ref. | |||||||
| 30–39 | 2.12 | (0.96, 4.71) | 0.0648 | ||||||
| 40–49 | 4.99 | (2.29, 10.90) | <0.0001 | ||||||
| 50–59 | 5.99 | (2.74, 13.11) | <0.0001 | ||||||
| 60–69 | 7.47 | (3.39, 16.48) | <0.0001 | ||||||
| ≥70 | 4.52 | (1.96, 10.45) | 0.0004 * | ||||||
| Income (NTD, New Taiwan Dollars) | |||||||||
| <10,000 | 1.00 | Ref. | 1.00 | Ref. | |||||
| 10,000–29,999 | 0.47 | (0.31, 0.73) | 0.0006 * | 0.60 | (0.38, 0.94) | 0.0254 * | |||
| >30,000 | 0.44 | (0.22, 0.88) | 0.0207 * | 0.58 | (0.28, 1.17) | 0.1273 | |||
| Education | |||||||||
| ≤6 years | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| 7–9 years | 0.48 | (0.30, 0.76) | 0.0018 * | 0.68 | (0.40, 1.15) | 0.1538 | 0.59 | (0.34, 1.04) | 0.0676 |
| 10–12 years | 0.32 | (0.19, 0.54) | <0.0001 | 0.46 | (0.26, 0.83) | 0.0100 * | 0.44 | (0.24, 0.83) | 0.0103 * |
| >12 years | 0.33 | (0.14, 0.79) | 0.0126 * | 0.55 | (0.21, 1.41) | 0.2127 | 0.73 | (0.27, 1.97) | 0.5380 |
| Current cigarette smoker | |||||||||
| No | 1.00 | Ref. | 1.00 | Ref. | |||||
| Yes | 1.03 | (0.66, 1.61) | 0.9000 | 1.39 | (0.86, 2.23) | 0.1806 | |||
| Alcohol drinking habit | |||||||||
| No | 1.00 | Ref. | 1.00 | Ref. | |||||
| Yes | 1.30 | (0.86, 1.96) | 0.2081 | 1.51 | (0.99, 2.31) | 0.0558 | |||
| Betel nut chewing habit | |||||||||
| No | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| Yes | 1.52 | (0.87, 2.65) | 0.1432 | 2.21 | (1.22, 4.00) | 0.0087 * | 1.64 | (0.86, 3.13) | 0.1358 |
| Uric acid | |||||||||
| Normal | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| Abnormal (>8 mg/dL) | 1.93 | (1.24, 3.02) | 0.0039 * | 2.31 | (1.43, 3.74) | 0.0007 * | 2.06 | (1.22, 3.48) | 0.0071 * |
| Total cholesterol | |||||||||
| Normal | 1.00 | Ref. | 1.00 | Ref. | |||||
| Abnormal (≥200 mg/dL) | 1.65 | (1.16, 2.34) | 0.0052 * | 1.47 | (1.02, 2.12) | 0.0367 * | |||
| AST | |||||||||
| Normal | 1.00 | Ref. | 1.00 | Ref. | |||||
| Abnormal (>34 U/L) | 1.47 | (0.96, 2.24) | 0.0756 | 1.68 | (1.09, 2.61) | 0.0199 * | |||
| ALT | |||||||||
| Normal | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| Abnormal (>36 U/L) | 1.85 | (1.21, 2.83) | 0.0043 * | 2.32 | (1.49, 3.62) | 0.0002 * | 2.02 | (1.24, 3.29) | 0.0046 * |
| γ-GT | |||||||||
| Normal | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| Abnormal | 2.06 | (1.36, 3.11) | 0.0006 * | 2.56 | (1.65, 3.97) | <0.0001 | 1.86 | (1.13, 3.07) | 0.0144 * |
| Creatinine | |||||||||
| Normal | 1.00 | Ref. | 1.00 | Ref. | 1.00 | Ref. | |||
| Abnormal | 6.55 | (1.86, 23.06) | 0.0035 * | 4.82 | (1.33, 17.40) | 0.0164 * | 5.38 | (1.25, 23.10) | 0.0237 * |
| Hepatitis B surface antigen (HBsAg) | |||||||||
| Negative | 1.00 | Ref. | 1.00 | Ref. | |||||
| Positive | 0.77 | (0.49, 1.23) | 0.2726 | 0.79 | (0.49, 1.26) | 0.3163 | |||
| Anti-HCV antibody | |||||||||
| Negative | 1.00 | Ref. | 1.00 | Ref. | |||||
| Positive | 1.75 | (0.80, 3.81) | 0.1619 | 1.52 | (0.68, 3.37) | 0.3048 | |||
* p-Value < 0.05.